Embolic Protection Devices Slowly Solidifying a Presence in Interventional cardiology

(Amherst, NH) – For the millions of patients of cardiovascular disease, peripheral artery disease, and related vascular insufficiency conditions, interventional cardiology is a primary therapeutic avenue for alleviating symptoms and improving quality of life. Until recently, practitioners and their patients have had to deal with the uncertainty associated with complications due to procedure-related embolic events. For these patients, the evolving capabilities of embolic protection devices (EPD) have become an essential element in treatment decisions and therapeutic outcomes.

While the evolutionary success of embolic protection devices has been impressive, several issues must be addressed in order for the technology to fully expand beyond SVG, PCI, and carotid artery procedures. Promising indications for embolic protection include atrial fibrillation-related embolism protection and interventional procedures for cerebrovascular defects.

This sector has been marked by a high level of technology acquisition activity, as established players in the embolic protection devices market seek to protect their existing franchise and expand product offerings.  Several companies are developing novel approaches to embolic protection that offer unique advantages. These technologies, while in early clinical trial stages, have the potential to influence the direction of future programs and alliance activity.

These findings are contained in a new report that analyzes embolic protection devices and their therapeutic applications. The report is designed to provide readers with a detailed understanding of approved and development-stage embolic protection devices, and the evolving technology and design issues shaping this segment

Source: Greystone Associates